Surprisingly, we found that the dose response of permeabilized CLL cells to venetoclax in this assay could not be readily distinguished from that of the responses to drugs inhibiting MCL1, BCLXL, or to ABT-737 which targets BCL2, BCLXL and BCLW. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.